Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes ...

Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish ...

If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter ...

CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical ...

Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after detecting anomalous echocardiographic readings in healthy volunteers that could ...

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call ...

Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...

In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa ...

The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...

While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized. In an effort to cut ...